Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Consumer sentiment hits a record low just as Berkshire Hathaway's 13F reveals a new Macy's position. The June print decides if the entry is a turnaround buy or a trap.
One-time gain masks 3% revenue growth. Operating cash flow pressured. Next quarter EBITDA will test turnaround story for the telecom operator.
Virgin Galactic Q1 2026 deck reveals cash burn, flight cadence, and Delta-class timeline. Investors should scan for one number above all others: the cash balance at quarter end.
Credit Saison published its Q4 fiscal 2026 slide deck. Investors should scan credit quality metrics, loan growth, and capital adequacy for the Japanese consumer lender.
Rakus Co., Ltd. released its Q4 fiscal 2026 earnings deck. Investors should focus on segment trends, margin trajectory, and any forward guidance in the slides.
Koç Holding published its Q1 2026 slide deck on May 15. Focus on segment margins, macro overlay, and cash flow for watchlist decisions.
Griffon released its Q2 fiscal 2026 earnings slide deck. Investors should focus on Home & Building Products and Defense segment trends for the stock's next move.
GPGI released its Q1 fiscal 2026 earnings presentation. Without specific figures yet, investors should focus on margin trends, cash flow, and forward guidance in the slides.
Miller Industries Q1 revenue hit $298M, gross margin expanded 230 bps to 14.8%. Towing demand and stable steel costs drove the beat. Free cash flow of $14M supports dividend outlook.
MiNK Therapeutics presented Phase II gastric data at AACR and IPF findings at Keystone. The stock's next move depends on partnership interest and cash runway.
VolitionRx Q1 revenue ~$1M, cash $3.1M. First DETECSEPS patient expected September. $5M milestone and Nu.Q Vet/Fuji catalysts ahead. Lung cancer program also pending.
Vecima Networks published its Q3 fiscal 2026 slide deck without a press release. Investors must scan for segment revenue, margin, and guidance signals. The next catalyst is the earnings call or MD&A filing.
A tech professional earning Rs 2.8 lakh/month reports minimal savings, a risk for India's high-income consumption. Q2 discretionary spending data is the next test.
Revenue fell 23% and a net loss of $34.4M emerged, even as core earnings dipped 16%. The full filing will reveal the driver behind the divergence.
doValue confirmed its EUR 300M EBITDA target, with Coeo outperforming expectations on revenue, margin, and early synergies. Next test: half-year quantification of that synergy ramp.
The May 15 Q3 call for Corby Spirit (CSW.A:CA) left investors without revenue or margin data after the transcript cut off mid-sentence. Full financials are still pending.
The equity-based acquisition of Oratech gives Lifeward protein oral delivery technology while introducing dilution and integration risk as the company targets profitability.
OBDC's Q1 2026 net investment income missed and the dividend was cut. The reset aligns payout with sustainable earnings. Next catalyst: portfolio repositioning and credit quality.
NANO Nuclear Energy held its Q2 2026 call on May 14, but the initial transcript summary did not include revenue, earnings, or cash figures. The full SEC filing will provide the numbers that matter for the microreactor developer’s funding runway.
First quarter sales and EBITDA beat guidance, management flagged softer RV demand. The beat may reflect cost control rather than volume strength. Next test: the 10-Q filing and summer RV retail registrations.
Q1 same-store sales rose 5%; management flagged tariff and freight cost headwinds that could pressure margins into fiscal 2027.
The initial Q4 FY2026 call transcript for Boot Barn omits revenue, EPS, and guidance. The press release and supplemental presentation contain the actual results.
The redemption of RZB raises questions about RGA's capital structure and the risk profile of its $164 billion asset base. Next catalyst: details on the financial instruments affected.
Live Ventures held its fiscal Q2 2026 call on May 14, but the transcript provided no financial figures. The stock's next move hinges on the 10-Q filing.
The May 14 earnings call transcript omitted Q3 financial details. The full 10-Q for the March 31 quarter remains pending, creating an information gap for RSSS stock.
The May 14 call transcript lists CEO Gregory Haskell and Chief Growth Officer Roland Austrup but no revenue or guidance. The 10-Q filing is the next data point.
Legacy Education ($LGCY) posted 15% revenue growth and margin gains in Q3, outlining campus expansions to add 1,200-1,500 students. Cash-rich balance sheet.
The May 14 call transcript provided no revenue, margin, or enrollment figures. Investors now await the 10-Q filing for the quarter's actual performance.
Avita Medical posted $19.3M in Q1 revenue and reaffirmed its $80M-$85M full-year view. Medicare rate normalization removes the key adoption headwind; the 2H revenue ramp is the next catalyst.
Professional services revenue fell 14.3% to $1.9M, extending a post-renewal slump. SaaS held flat. Cash of $2.1M and no debt provide runway; the double-digit SaaS growth target now requires a sharp acceleration.